How should a company model prior authorization impact on commercial adoption?

Modeling commercial uptake without accounting for prior authorization denial rates and the time and administrative burden of the appeals process significantly overstates how quickly a new device or service will actually reach patients, since even clinically appropriate cases can be delayed or denied on an initial PA request. Companies increasingly build clinical pathway tools, coding support, and PA appeal assistance directly into their commercial model to reduce this friction, treating PA support as a core part of market access rather than an afterthought.

What information does a payer typically require to approve a prior authorization request?

Payers generally require documentation demonstrating medical necessity based on their specific coverage criteria, which can include clinical notes, prior conservative treatment history, relevant diagnostic results, and sometimes adherence to a specific clinical guideline or society recommendation, and these criteria vary meaningfully across payers and even across plans within the same payer. A device manufacturer that provides standardized documentation templates or clinical pathway support to ordering physicians can materially reduce PA denial rates compared to leaving providers to navigate payer-specific requirements alone.

How does CMS prior authorization reform affect MedTech market access planning?

CMS has pursued reforms aimed at streamlining prior authorization timelines and increasing transparency around denial rates and criteria, particularly for Medicare Advantage plans, and companies tracking these reforms should anticipate that PA processes for Medicare-covered devices may change materially over the coming years. Because commercial payers do not automatically follow CMS policy changes, a company's market access strategy generally needs a payer-by-payer view of PA requirements rather than assuming Medicare rules apply uniformly across all coverage.

Back to Reimbursement & Market Access

ReimbursementHospital Buyer & Reimbursement

Prior Authorization

Payer requirement for approval before a service or device is covered.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Prior authorization (PA) is a payer process requiring providers to obtain approval - based on medical necessity criteria - before a service, procedure, or device is covered. Common for high-cost devices, advanced imaging, and many DTx/RPM services. Payers use clinical criteria such as their own policies, InterQual or MCG guidelines, and decisions can be appealed. CMS's 2024 Interoperability and Prior Authorization rule requires Medicare Advantage, Medicaid and some other plans to speed decisions and add electronic prior authorization interfaces in stages starting in 2026. Device companies often fund patient access support teams to help with paperwork.

What the regulation says

CMS's Interoperability and Prior Authorization Final Rule, CMS-0057-F (89 FR 8758, published February 8, 2024; effective April 8, 2024), establishes requirements for Medicare Advantage organizations, Medicaid and CHIP programs and managed care plans, and qualified health plan issuers on federally facilitated exchanges. Beginning January 1, 2026, affected payers, except those exchange issuers, must issue prior authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests. Shorter applicable deadlines still control. The rule also requires affected payers to provide specific reasons for denials and publicly report prior authorization metrics, with these operational requirements beginning in 2026. Its prior authorization provisions exclude drugs. The rule generally requires implementation of a standards-based Prior Authorization API beginning January 1, 2027. This interface must help providers identify covered services requiring authorization, determine documentation requirements, and submit requests and receive responses electronically. These obligations modernize the process rather than establish uniform medical necessity criteria or guarantee coverage. For MedTech companies, FDA marketing authorization and payer authorization remain distinct: permission to market a device does not itself establish reimbursement. Patient access support should therefore follow the applicable payer's documentation, coverage, and appeal requirements.

What this means in practice

PA is a major friction point for new technology adoption; clinical pathway and PA support tools are increasingly part of the manufacturer commercial model.

Examples

A patient requires a specialized implantable device for a complex cardiac condition. The cardiologist must submit a prior authorization request to the patient's health insurance, detailing medical necessity and expected benefits before the device can be approved for coverage and surgical implantation.
A physician prescribes a new digital therapeutic for chronic pain management. The clinic's billing department is responsible for obtaining prior authorization from the patient's payer, often involving submitting clinical documentation to demonstrate that the patient meets the payer's specific criteria for the therapy.
Prior to a patient undergoing an advanced diagnostic imaging procedure, such as a high-resolution MRI, the ordering physician's office must contact the insurance provider for prior authorization. This often requires providing clinical justification to ensure the procedure is deemed medically necessary according to the payer's guidelines.

Common pitfalls

•Underestimating PA denial rates and appeal timelines when modeling commercial uptake.

Frequently asked questions

Payers use prior authorization as a utilization management tool specifically for services where cost, variability in appropriate use, or new-technology status create financial risk to the plan, which is why advanced imaging, high-cost implants, and many newer digital therapeutics or remote monitoring services are common PA targets while routine, low-cost, well-established procedures typically are not. As a device or service category matures with established clinical guidelines and predictable utilization patterns, payers sometimes relax PA requirements, but new MedTech categories should generally expect PA friction at launch.

Grouped by theme

Reimbursement & Market Access

· From this learning path

Reimbursement

Health Technology Assessment(HTA)

Systematic evaluation of clinical and economic value of a health technology.

Adjacent lesson

Reimbursement

Transitional Coverage for Emerging Technologies(TCET)

CMS pathway providing time-limited Medicare coverage for FDA-designated Breakthrough Devices.

Adjacent lesson

Reimbursement

Budget Impact Model(BIM)

Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.

Reimbursement

CPT Codes(CPT)

AMA-maintained codes that describe medical procedures and services.

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

CMS·1AMA·1AdvaMed·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Reimbursement0 / 37

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Reimbursement
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Payer requirement for approval before a service or device is covered.

·PA is a major friction point for new technology adoption; clinical pathway and PA support tools are increasingly part of the manufacturer commercial model.
·Common for high-cost devices, advanced imaging, and many DTx/RPM services.
·Payers use clinical criteria such as their own policies, InterQual or MCG guidelines, and decisions can be appealed.

Remember this

Watch out: Underestimating PA denial rates and appeal timelines when modeling commercial uptake.

You may also need

Auto-suggested from Reimbursement and shared keywords.

All Reimbursement terms

Definition

What this means in practice

Examples

Frequently asked questions

Related terms

Reimbursement & Market Access

More in Reimbursement

Latest in MedTech

Sources